Member Info for BOJO2020

Thanks BermudaShorts,

Sorry for the open question but what are we looking for in the ovarian study. What I mean is how do we know if the results are good. Specificity, sensitivity? Is there a comparable study that you are aware of?

Many Thanks

I appreciate it’s a big question

Well I have ran out of Mars Bars but if I had one I would give it to you. Is a hearty well done acceptable?

That moment has been for over a year. The knack is to keep buying back so as accumulate a decent holding

I put some of these highly emotional and irrational posts down to peoples brains being overheated.

We are looking @ £1k per test with a gross margin of 70% (according to the CEO)

I believe the average order value has been estimated @ £1k to £2K

So you could look at it many ways. For instance:

1. The A.O.V is £1.5K with 70% GM

Or, as I would prefer to do, use the sensitivity model that is common in business planning

For Instance the A.O.V would be

Sensitivity A £1.5k
Sensitivity B £1.25k
Sensitivity C £1.1k

The reason for the A,B,C would be the structure of a test. So lets say a two part test both @ £1k each = £2k (GM 70%) A single part test being £1k (GM 70%)
Or you might say there are far less two part tests than expected in sensitivity A, or for some unforeseen reason the GM is heavily eroded (say 50%) then you would be looking at sensitivity B or C.

Just so you know, these calculations are common place in business for the purposes of proving potential profitability, cash flows, balance sheet exercises etc. In other words they are a planning tools so I think you are barking up the wrong tree!

Good luck anyhow.

SC & PM

I think you have a point

Route to market via Solaris. A US giant that has 750k patients… just one example of what IS happening as we sit and contemplate.

Some me people like AN have the temperament and appetite to do, but we shall wait and see.

1. Angle have NO debt.
2. We have £40 million plus cash.
3. We have a 18 month commercial strategy.
4. Angle have a strong track record of regular positive news (go read RNS's, no reason to doubt this is going to stop).
5. HyCead.
6. Parsortix device is now FDA approved in MBC. Other cancer types to follow.
7. Ovarian Study imminent.
8. Solaris Study underway (estimated timeline for headline results 9 months).
9. Share price discounted by 25% (from £1.00 which I believe to be base camp).
10. Latest fund raise was hardly dilutive (hardly any extra shares issued).
11. Clinical labs have 4 customers with several contracts (more to follow in pipeline).
12. CLIA accreditation to follow in due course.

We are all on other platforms and no ramping just facts. Usually news up to a week before here

PJ12,

Cancer profiling is critical. Both Cellsearch & Parsortix (liquid biopsy) should be researched thoroughly by anyone invested in cancer drugs and therapies. As should traditional tissue biopsy to which Parsortix has been given exact parallel status by FDA in MBC. In short, both traditional biopsy and Parsortix give DNA, RNA and specific protein data that cannot be achieved by other means. They stand alone.

That said, there are some bloody clever people in these drug development companies who have such a deep and substantive understanding of the immune system and cancer that they can can find alternative routes. I think such people are amazing.

Wyndham,

Your Friday 9.05

Unfortunately cancer evolves and changes. Once cancer spreads to a secondary site the mean survival rate is 10%. The point of chemo is to destroy cancer before it spreads. I would imagine this is what Avacta are trying to achieve

Are you unhappy about something in particular?

Wow that’s so spooky! I was reading a book the other day and I swear it was just like reading some of the posts on here. Now what’s was it called…

Ah yes I remember now. Chicken Licken :-). Apparently it’s quite a regularly phenomenon among impatient investors that fall into a negative mental spiral

Hi Brex,

Definitely 9 months to negotiate the first deal with that pharma and 90 minutes for repeat business!

I am not sure people are picking up the snowball effect of contracts. Especially when they as a whole, pass a critical mass. It was always going to be tough starting labs and gaining momentum from a standing start. These are the hard yards right now. In coming months the momentum will increase

AN said 9 months to negotiate with one pharma contract but you folks want it done in weeks since FDA approval!

Researcher1,

You know exactly what I mean. Some people do not have a clue about commercialisation. They have simply joined the que that is signed, ‘Abbot buying here so hold tight.’ The problem with that idea of course is that there is no timeframe. If you don’t have a timeframe then what do you have, hope? Pull the other one. So let’s get on with business and adding value.

Maybe the ideal scenario is a drawn out partnership that leads to a buyout.

I sometimes think that people are expecting a multi billion deal from Abbot to buy Angle tomorrow. Forgetting entirely or not willing to accept that we are a real business and need to put the hard yards in. Much rather Angle build value over time. I expect a lot of deals to be announced over the next year. No shortcuts people!

that Scancell were busy behind the scenes and not to panick.

Try and remember this the next time you find yourselves having a hissy fit about the lack of news.

Gold stocks are struggling which is a sign we are near bottom. FTSE needs to crash first. Then gold rally, followed by silver. Then in a couple of years by AIM. Hold tight!

Scratch the itch buy grabbing some and then wait for 75 or 95p. It will go one way or the other. I btw have been very itchy lately!

The proliferation of CTC’s and clusters is different in each cancer and from patient to patient.